Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review

References

• Kim SJ, Cegelski L, Stueber D, et al. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol. 2008;377:281–293.
   PubMed Web of Science ®Google Scholar
• Arhin FF, Sarmiento I, Parr TR Jr, Moeck G. Mechanisms of action of oritavancin in Staphylococcus aureus. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007; Chicago, IL.
   Google Scholar
• Belley A, Neesham-Grenon E, Arhin FF, McKay GA, Parr TR Jr, Moeck G. Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob Agents Chemother. 2008;52:3820–3822.
   PubMed Web of Science ®Google Scholar
• Belley A, Neesham-Grenon E, McKay G, et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother. 2009;53:918–925.
   PubMed Web of Science ®Google Scholar
• McKay GA, Beaulieu S, Belley A, Arhin FF, Parr TR Jr, Moeck G. In vitro time kill studies of oritavancin against drug-resistant isolates of Staphylococcus aureus and enterococci. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007; Chicago, IL.
   Google Scholar
• Lehoux D, Arhin FF, Fadhil I, et al. Oritavancin demonstrates rapid and sustained bactericidal activity in the rat granuloma pouch model of Staphylococcus aureus infection. Presented at: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006; San Francisco, CA.
   Google Scholar
• Van Bambeke F, Carryn S, Seral C, et al. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob Agents Chemother. 2004;48:2853–2860.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Gotfried MH, Loutit JS, Porter SB. Plasma and intrapulmonary concentrations of oritavancin and vancomycin in normal healthy adults. Presented at: 14th European Congress of Clinical Microbiology and Infectious Diseases; 2004; Prague.
   Google Scholar
• Belley A, Neesham-Grenon E, Parr TR Jr, Moeck G. Pharmacokinetic concentrations of oritavancin kill stationary-phase and biofilm Staphylococcus aureus in vitro. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007; Chicago, IL.
   Google Scholar
• Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med. 2004;350:1422–1429.
   PubMed Web of Science ®Google Scholar
• Lemaire S, Kosowska-Shick K, Julian K, Tulkens PM, Van Bambeke F, Appelbaum PC. Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis. Clin Microbiol Infect. 2008;14:766–777.
   PubMed Web of Science ®Google Scholar
• Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001;358:135–138.
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis. 2004;50:95–102.
   PubMed Web of Science ®Google Scholar
• Chien J, Allerheiligen S, Phillips D, Cerimele B, Thomasson HR. Safety and pharmacokinetics of single intravenous doses of LY333328 diphosphate (glycopeptide) in healthy men. Presented at: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998; San Francisco, CA.
   Google Scholar
• Rubino CM, Van Wart SA, Bhavnani SM, Ambrose PG, McCollam JS, Forrest A. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother. 2009;53:4422–4428.
   PubMed Web of Science ®Google Scholar
• Fetterly GJ, Ong CM, Bhavnani SM, et al. Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose. Antimicrob Agents Chemother. 2005;49:148–152.
   PubMed Web of Science ®Google Scholar
• Belley A, Arhin FF, Moeck G. Oritavancin does not antagonise the activity of common antibacterial agents for Gram-positive and Gram-negative infections. Presented at: 24th European Congress on Clinical Microbiology and Infectious Diseases; 2014; Barcelona.
   Google Scholar
• Rowe PA, Brown TJ. Protein binding of 14C-oritavancin. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001; Chicago, IL.
   Google Scholar
• Lehoux D, Okusanya OO, Laquerre K, Forrest A, Ostiguy V, Bhavnani SM. PK-PD of oritavancin (ORI) against Streptococcus pneumoniae (SP) in a murine-pneumonia infection model. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007; Chicago, IL.
   Google Scholar
• Poulakou G, Giamarellou H. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens. Expert Opin Investig Drugs. 2008;17:225–243.
   PubMed Web of Science ®Google Scholar
• Sahm DF, Draghi DC, Moeck G, Arhin FF. Longitudinal study of the activity of oritavancin (ORI) against Staphylococcus aureus (SA) from Europe (EU) between 2011 and 2013. Presented at: 24th European Congress on Clinical Microbiology and Infectious Diseases; 2014; Barcelona.
   Google Scholar
• Mendes RE, Farrel DJ, Flamm RK, Sader HS, Jones RN. Activity of oritavancin and comparator agents against multidrug-resistant staphylococcal and streptococcal isolates responsible for documented infections in European hospitals (2011–2013). Presented at: 24th European Congress on Clinical Microbiology and Infectious Diseases; 2014; Barcelona.
   Google Scholar
• Mendes RE, Farrel DJ, Streit JM, Jones RN. Current analysis of oritavancin potency when tested against vancomycin-resistant/susceptible enterococcal clinical isolates recovered from European medical centres (2009–2013). Presented at: 24th European Congress on Clinical Microbiology and Infectious Diseases; 2014; Barcelona.
   Google Scholar
• Morrissey I, Seifert H, Canton R, et al; Oritavancin Study Group. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011. J Antimicrob Chemother. 2013;68:164–167.
   PubMed Web of Science ®Google Scholar
• Arhin FF, Sarmiento I, Moeck G. In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene. Int J Antimicrob Agents. 2014;44:65–68.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Flamm RK, Sader HS, Jones RN. Oritavancin activity tested against Staphylococcus aureus and β-haemolytic streptococci causing skin and soft tissue infections in European Union and other countries (2010–2012). Presented at: 23rd European Congress on Clinical Microbiology and Infectious Diseases; 2013; Berlin.
   Google Scholar
• Deane J, Opeila C, Moeck G, Arhin FF, Sahm DF. Activity of oritavancin against European bacterial pathogens associated with skin/wound and soft tissue infections and bacteraemia. Presented at: 23rd European Congress on Clinical Microbiology and Infectious Diseases; 2013; Berlin.
   Google Scholar
• Linden PK. Vancomycin resistance: are there better glycopeptides coming? Expert Rev Anti Infect Ther. 2008;6:917–928.
   PubMed Web of Science ®Google Scholar
• Okusanya OO, Lehoux D, Van Wart SA, et al. Pharmacokinetics and pharmacodynamics of oritavancin against Staphylococcus aureus in a neutropenic murine thigh-infection model. Presented at: William A Craig Symposium of the International Society of Anti-infective Pharmacology; 2008; Madison, WI.
   Google Scholar
• Forrest A, Cadieux C, Lehoux D, et al. Efficacy of oritavancin (ORI) in the mouse bacteremia model. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America 46th Annual Meeting; 2008; Washington, DC.
   Google Scholar
• Kaatz GW, Seo SM, Aeschlimann JR, Houlihan HH, Mercier RC, Rybak MJ. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1998;42:981–983.
   PubMed Web of Science ®Google Scholar
• Saleh-Mghir A, Lefort A, Petegnief Y, et al. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis. Antimicrob Agents Chemother. 1999;43:115–120.
   PubMed Web of Science ®Google Scholar
• Dunbar LM, Milata J, McClure T, Wasilewski MM; SIMPLIFI Study Team. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother. 2011;55:3476–3484.
   PubMed Web of Science ®Google Scholar
• Corey GR, Kabler H, Mehra P, et al; SOLO I Investigators. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370:2180–2190.
   PubMed Web of Science ®Google Scholar
• Wasilewski MM, Disch DP, McGill JM, Harris HW, O’Riordan WD, Zeckel ML. Equivalence of shorter course therapy with oritavancin vs. vancomycin/cephalexin in complicated skin/skin structure infections. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001; Chicago, IL.
   Google Scholar
• Giamarellou H, O’Riordan WD, Harris HW, Owen JS, Porter SB, Loutit JS. Phase III trial comparing 3–7 days of oritavancin vs 10–14 days of vancomycin/cephalexin in the treatment of patients wiht complicated skin and skin structure infections (cSSI). Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003; Chicago, IL.
   Google Scholar
• Moriarty SR, Wasilewski MM, Rosen AS, Perry M. Incidence of histamine-like infusion reactions in 2 Phase III studies comparing oritavancin and vancomycin in the treatment of complicated skin and skin structure infections. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2008; Washington, DC.
   Google Scholar
• Moriarty SR, Wasilewski MM, Rosen AS, Perry M. Safety of oritavancin versus vancomycin for treatment of patients with complicated skin and skin-structure infections. Presented at: 19th European Congress on Clinical Microbiology and Infectious Diseases; 2009; Helsinki.
   Google Scholar
• Friedman HL, Moriarty SR, Hund ME, Lee SK, Mason JW, Moon TE. A Phase I, double-blind, randomized, placebo- and postive-controlled, single dose, parallel design trial to assess the potential electrocardiographic effects of oritavancin in healthy adults. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2008; Washington, DC.
   Google Scholar
• Targanta Therapeutics Corporation. NUVOCID® (oritavancin diphosphate for injection) for Treatment of Complicated Skin and Skin Structure Infections. Available from: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4394b2-04-Targanta.pdf. Accessed January 20, 2015.
   Google Scholar